Sham Mailankody, MBBS, on Further Research With ALLO-715
The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.
“Can we understand why some patients have a long response and others don't? Can we understand the importance of antigen BCMA expression at baseline and at the time of relapse, and correlations with how high the CAR T expands? How long do the cells persist? Some of this is data that we're currently trying to generate to try and better understand how we can get more patients with these2+year responses.”
ALLO-715 (Allogene), an allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, had a manageable safety profile with promising efficacy in patients with relapsed/refractory multiple myeloma (R/R MM) in the phase 1 UNIVERSAL open-label trial (NCT04093596). These data, which includedan objective response rate of 65% and a very good partial response rate of about 50%, were presented by Sham Mailankody, MBBS, associate attending physician, Memorial Sloan Kettering Cancer Center, 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana.
CGTLive spoke with Mailankody to learn more about ALLO-715 and research that remains to be done and questions that remain to be answered with the therapy and with cell therapy for R/R MM in general. He also discussed advantages of allogeneic therapies over autologous therapies.
